pharmacology of diabetes mellitus Flashcards

1
Q

type one diabetes characteristics - common, population, onset, symptoms, insulin?

A

uncommon, 10% childhood, sudden onset, insulin needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

characteristics of T2DM

A

adult onset, 90%, 40 years over, common, onset is gradual, may or may not have symptoms , insulin required by some people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

best practice pharmacotherapy for T1DM

A

multiple daily injections, continous subcutaneous insulin infusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

example of subcutaneous insulin infections

A

insulin pumos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is basal insulin

A

this is insulin that runs in the background

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is bolus insulin

A

this is insulin that is secreted in response to energy intake ans glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

is an insulin is short acting, when should you administer it

A

inject before eating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

if an insulin is fast acting, when should you inject

A

after you have eaten

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the pathophysiology of T2DM

A

when there is decreased insulin by the pancreas and increased glucagon secretion in islet cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pharmacotherapy for T2DM

A

oral or injectable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

examples of oral pharmacotherapy management

A

medication by mouth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what injectable and oral medications would we want ideally for pharmacotherpay for T2DM

A

drugs that can help decreased blood sugar and chances of heart issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what risk factors should be considered with T2DM

A

risk of heart issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is biguanide, what does it do

A

enhances insulin sensitivity in live and peripheral tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what does biguanide activate

A

AMP - activated protien kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

glucagon like peptide

A

injectable once a week, works to activate the incretin pathway

17
Q

sodium glucose co-transporter 2 inhibitor

A

works on the kidneys to get rid of extra glucose

18
Q

dipeptidyl peptidase-4 inhibitor

A

works to amplify the incretin pathway activation by inhibition of enzymatic breakdown of GLP-1 and GIP

19
Q

works to amplify the incretin pathway activation by inhibition of enzymatic breakdown of GLP-1 and GIP

A

dipeptidyl peptidase-4 inhibitor

20
Q

what is the incretin pathway

A

after eating, gut hormones are secreted into blood and enteroendocrine cells

21
Q

what is the role of the incretin pathway

A

to manage/regulate the amount of insulin secreted

22
Q

how does insulin work

A

activates insulin receptors to regulate metabolism of carbohydrates, fats and protien

23
Q

what do thiazolidinediones do?

A

they work to make the body more sensitive to insulin

24
Q

alpha glucosidase inhibitor

A

inhibits the pancreatic alpha-amylase and intesinal alpha glucosidase or delay the absorption of carbohydrates from the small intestine, lowering the effect on glucose levels

25
Q

what are the most lethal treatment for t2dm

A

insulin secretagogues

26
Q

how do insulin secretagogues work?

A

they activate sulfonylurea receptor on beta cell to stimute endogenous insulin secretion

27
Q

how do anti-obesity agents work?

A

inhibit lipase

28
Q

what are some considerations for agent characteristics concerning the pharmacotherapy of T2DM

A

blood glucose lowering the efficacy and durability, risk of inducing hypoglycemia, effect on weight, side effects, cost, cardioprotection

29
Q

blood glucose lowering the efficacy and durability, risk of inducing hypoglycemia, effect on weight, side effects, cost, cardioprotection are what?

A

agent characteristics

30
Q

what are some patient characteristics that should be considered when considering pharmacotherapy??

A

degree of hyperglycemia, risk of hypoglycemia, weight, comorbidities, preferences, access to treatment

31
Q

what are some comorbidities

A

renal and hepatic issues, insulin secretagogues can increase this risk